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Raj Kumar1, Michael Taylor1, Benchun Miao1, Zhenyu Ji1, Jenny C-N Njauw1, Go¨ran Jo¨nsson2,
Dennie T. Frederick3 and Hensin Tsao1
Although the pattern of BAP1 inactivation in ocular melanoma specimens and in the BAP1 cutaneous melanoma
(CM)/ocular melanoma predisposition syndrome suggests a tumor suppressor function, the specific role of this
gene in the pathogenesis of CM is not fully understood. We thus set out to characterize BAP1 in CM and discovered
an unexpected pro-survival effect of this protein. Tissue and cell lines analysis showed that BAP1 expression was
maintained, rather than lost, in primary melanomas compared with nevi and normal skin. Genetic depletion of BAP1
in melanoma cells reduced proliferation and colony-forming capability, induced apoptosis, and inhibited melanoma
tumor growth in vivo. On the molecular level, suppression of BAP1 led to a concomitant drop in the protein levels of
survivin, a member of anti-apoptotic proteins and a knownmediator of melanoma survival. Restoration of survivin in
melanoma cells partially rescued the growth-retarding effects of BAP1 loss. In contrast to melanoma cells, stable
overexpression of BAP1 into immortalized but non-transformed melanocytes did suppress proliferation and reduce
survivin. Taken together, these studies demonstrate that BAP1 may have a growth-sustaining role in melanoma cells,
but that its impact on ubiquitination underpins a complex physiology, which is context and cell dependent.
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INTRODUCTION
The BRCA1-associated protein 1 (BAP1) gene is a recent
addition to the canon of high-risk melanoma susceptibility
genes. Many groups have described germline BAP1 alterations
in families predisposed to cutaneous melanoma (CM) and
ocular melanoma among other malignancies (Harbour et al.,
2010; Abdel-Rahman et al., 2011; Wiesner et al., 2011;
Njauw et al., 2012). To date, both heritable and acquired
mutations in BAP1 have been deleterious with loss-of-
heterozygosity described in melanoma tumor specimens
(Wiesner et al., 2011; Njauw et al., 2012). This genetic
pattern suggests a tumor suppressor function for the BAP1
protein. However, unlike ocular melanomas, CMs do not
commonly harbor BAP1 mutations outside of the familial
context (Harbour et al., 2010; Wiesner et al., 2011; Njauw
et al., 2012). More importantly, the role of BAP1 in the
pathogenesis of sporadic CM has yet to be fully characterized.
Functional analyses of BAP1 have yielded conflicting
results. Early experiments found that BAP1 enhanced
BRCA1-mediated inhibition of breast cancer cell growth
(Jensen et al., 1998). BAP1 has also been reported to be
inactivated in about 15% of renal cell carcinomas and has
been shown to be growth suppressive in functional assays
(Pena-Llopis et al., 2012). With the recognition that BAP1
directly interacts with HCF-1, there were hints that BAP1
could also have a positive proliferative role (Machida et al.,
2009). These findings were further substantiated by genome-
wide RNA suppression screens, which established BAP1 as an
essential proliferation and cell cycle gene (Kittler et al., 2007;
Schlabach et al., 2008). Even among uveal melanomas, where
the prevalence of deleterious mutations remains the highest,
recent studies suggest that BAP1 is not functionally
suppressive and that the biology of this deubiquitinase is
highly complex (Matatall et al., 2013).
We thus set out to better understand the role of BAP1 in
CM––one of the signature cancers in the BAP1 tumor predis-
position syndrome. Using a combination of genetic and
functional studies, we provide evidence that BAP1 may be
an important growth-sustaining protein that is linked to the
regulation of survivin––a known anti-apoptotic factor in
melanoma (McKenzie and Grossman, 2012).
RESULTS
Basal expression level of BAP1 in melanomas
We first examined the messenger RNA (mRNA) levels of BAP1
in primary melanocytic tumors using a set of 223 melanomas,
11 nevi, and 6 samples of normal tissue (Harbst et al., 2012)
and found no significant difference in relative BAP1
expression (Figure 1a), although levels may be slightly lower
in mucosal melanomas. When stratified by tumor features
(Figure 1b), BAP1 expression was increased in thin melano-
mas (o1 mm) and decreased in thick melanomas (44 mm)
compared with nevi and normal tissue; however, the
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Figure 1. BAP1 expression in primary cutaneous melanomas and melanoma lines. (a) BRCA1-associated protein 1 (BAP1) expression in histological types of
melanoma. (b) BAP1 expression melanomas stratified by Breslow thickness, BAP1 expression in relation to ulceration, and the mitotic rate. (c) Survival differences
between BAP1 high (4mean gene expression across the melanomas) and BAP1 low tumors (pmean gene expression across the melanomas). (d) Western blot
analysis showing relative protein levels of BAP1 in a collection of 16 melanoma cell lines, primary human melanocytes (PHMs), primary human fibroblasts (PHF),
and an immortalized non-transformed human melanocytes (Pmel). (e) Ranked BAP1 RNA levels (normalized to human GUSB) in a panel of melanoma lines and
PHM-1, PHM-2, and Pmel. (f) Correlation between normalized BAP1 protein (to GAPDH) and normalized BAP1 RNA (to Hu-GUSB). Pmel (red circle and red
asterisk) shows low RNA levels but strong protein expression, whereas PHM-2 (blue circle and blue asterisk) shows high RNA levels with a near absence of
detectable protein. LMM, lentigo maligna melanoma; mRNA, messenger RNA; NM, nodular melanoma; SSM, superficial spreading melanoma.
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difference across all groups was nonsignificant. Lower BAP1
expression was observed in primary melanomas with ulcera-
tion (P¼0.002) and higher mitotic rate (X6 mitoses versus
o6 mitoses; P¼ 0.04). Finally, when supervised by outcome,
primary melanomas with low BAP1 expression exhibited a
worse prognosis compared with those with high BAP1 levels
(Figure 1c), although these results were likely confounded by
its association with ulceration and the high mitotic rate. We
then examined BAP1 levels in an independent set of meta-
static melanomas (Gene Expression Omnibus GDS1375) and
identified a significant increase in the levels of BAP1 among
metastatic cases compared with normal tissue and nevi
(Supplementary Figure S1a online).
The levels of BAP1 in proliferating melanoma cells were
then determined. We first assessed BAP1 protein levels in 16
melanoma lines, 2 independent primary human melanocyte
lines (PHM-1 and PHM-2), a primary human fibroblast (PHF)
line, and an immortalized, but non-transformed, melanocyte
line (Pmel; Figure 1d). Except for PHM-2 and the PHF, there
was a robust protein expression in all samples. RNA expres-
sion was then examined in a broader panel of lines by
quantitative PCR (Figure 1e) and was found to be well
sustained in all the melanoma lines. Interestingly, protein
levels were generally constant, despite a gradient of RNA
expression (Figure 1e). One of the primary melanocyte lines,
PHM-2, showed negligible protein expression (Figure 1f) even
with relatively high RNA content (blue asterisk, blue circle),
whereas the immortalized melanocyte line, Pmel, demon-
strated strong BAP1 protein levels despite low RNA expression
(red asterisk, red circle). These findings indicate that mela-
noma cells, but not necessarily primary cells, preserve the
amount of intracellular BAP1. To replicate these findings and
to put melanoma in the context of other proliferating cancer
cells, we used the Cancer Cell Line Encyclopedia (N¼ 1,036
cancer lines) and found that the median expression of
BAP1 in 61 melanoma lines ranked ninth among the 37
cancer cell types (Supplementary Figure S1b online)
and was significantly higher compared with all non-melanoma
lines (Supplementary Figure S1b online; 7.59 vs. 7.33;
Po0.001, Student’s t-test). Thus, BAP1 appears central to
the survival of melanoma cells, although its role in primary
cells is less clear.
BAP1 depletion abrogates melanoma growth
To test the hypothesis that BAP1 contributes to the melanoma
cell maintenance, we examined the effects of BAP1 depletion
on the growth kinetics of melanoma cells. As shown in
Figure 2, depletion of BAP1 in two BRAF(V600E)-mutant lines
(A375 and SKmel-28, Figure 2a) and two NRAS(Q61R)-mutant
lines (SKmel-119 and SKmel-63, Figure 2b) led to marked
reductions in melanoma proliferation. These were also accom-
panied by significant decreases in the colony-forming capacity
of the BAP1-depleted cells (Figure 2c). Finally, we investigated
the effects of BAP1 loss on tumor growth in vivo using two
sh(BAP1)-suppressed lines (A375 and C918). As shown in
Figure 2d, BAP1 depletion diminished the tumorigenicity of
melanoma xenografts in immunocompromised mice. Exam-
ination of the tumor specimens demonstrated less Ki67 and
more TUNEL staining in the two sh(BAP1) tumors compared
with the control tumors (Supplementary Figure S2 online). This
suggests that BAP1 loss can produce similar anti-proliferative
and pro-apoptotic effects in vivo as found in vitro.
For the cell cycle and apoptosis assays (Figure 3), A375
[BRAF(V600E)], SKmel-119 [NRAS(Q61R)], and C918 (uveal
melanoma) cells were used. In 10% serum (Figure 3a),
suppression of BAP1 led to G2/M arrest with modest G1/S
effects. However, in 2.5% serum (Figure 3b), there were
appreciable increases in apoptosis as measured by subG1
fractionation; this apoptotic response was independently con-
firmed using FITC-Annexin staining (Figure 3c). These results
indicate that both cell cycle arrest and apoptosis may
contribute, in part, to the proliferative shut down observed
with BAP1 suppression in vitro.
BAP1 regulates survivin
We set out to identify potential mediators of BAP1-dependent
survival. As one of the IAP family members––BIRC5 or
survivin––has been implicated both as a viability factor in
melanoma and a target of BAP1 regulation in U2OS cells (Yu
et al., 2010), we hypothesized that BAP1 depletion may have
an effect on survivin levels. As shown in Figure 4a, BAP1
suppression led to a marked loss of survivin protein levels in
three of four cell lines examined (A375, SKmel-28, and C918);
quantitative PCR confirmed a concomitant loss of BIRC5
mRNA in A375 and SKmel-28, but not in C918, melanoma
cells. In one cell line (SKmel-119), there was a rise in BIRC5
mRNA and survivin protein levels. Thus, BAP1 effects are cell
context dependent and may exist at both transcriptional and
post-transcriptional levels. To determine whether the loss of
survivin was a necessary component of the growth inhibition
observed with BAP1 depletion, we overexpressed survivin in
the context of BAP1 loss. As shown in Figure 4b, there was a
consistent rescue of cell growth in the A375(shBAP1) cells
when survivin was overexpressed (Figure 4b; A375 (shBAP1/
BIRC5-OE) versus A375 (shBAP1)). In addition, if BIRC5 is
under BAP1 regulation, then one might expect a direct
relationship between the levels of the two genes. As shown
in Supplementary Figure S3a online, there was indeed a
significant correlation between BIRC5 and BAP1 mRNA levels
in the CCLE melanoma data set (P¼ 0.0026; N¼62). More-
over, BIRC5 loss was similarly associated with a worsened
outcome in the 223 primary melanomas (Supplementary
Figure S3b online; P¼ 0.0009). Taken together, these findings
suggest that BAP1 loss appears to have a negative impact on
survival factors and that downregulation of species such as
survivin may be one component of the BAP1 effect.
To examine more specific role of ubiquitination, we
performed a proteasome/protein clamp experiment using
A375 and C918 cell lines, both of which showed a loss of
survivin protein levels with BAP1 depletion and yet contrast-
ing effects on the BIRC5 mRNA level. Briefly, control and
BAP1-depleted A375 and C918 cells (i.e., A375 (nontargeting
control (NTC))/A375 (shBAP1) and C918 (NTC)/C918
(shBAP1)) were subjected to 6-hour pre-treatment with protea-
some inhibitor MG132 (25mM) to enrich for ubiquitinated
proteins. As shown in Supplementary Figure S4 online, total
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protein ubiquitination was markedly increased by the MG132
treatment. The cells were then removed from MG132 expo-
sure and treated with the protein synthesis inhibitor, cyclo-
heximide (25mg ml 1; transfer time¼ 0). The levels and decay
of BAP1 regulated protein(s) were then analyzed at 1, 2, 4,
and 6 hours after cycloheximide exposure using Western
blotting (Figure 4d). In untreated A375 and C918 cells, the
loss of BAP1 was associated with a marked reduction in
survivin levels (Figure 4d, control ‘‘C’’ lanes), consistent with
the prior analysis. MG132 treatment alone (‘‘þM’’ versus
‘‘C’’) led to increased survivin, suggesting that proteasomal
degradation modulates survivin levels. Both A375(shBAP1)
and C918(shBAP1) lines exhibited appropriate survivin decay
upon release of MG132 and inhibition of new protein
synthesis by cycloheximide, despite having attenuated survi-
vin protein levels at baseline. As BAP1 depletion led to
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Figure 2. BAP1 depletion leads to melanoma growth suppression. The short-hairpin RNA (shRNA)-mediated suppression of BRCA1-associated protein 1 (BAP1)
results in reduced in vitro proliferation in four cutaneous melanoma cell lines. (a) A375 and SKmel-28 harbor BRAF (V600E) mutations, whereas (b) SKmel-119 and
SKmel-63 contain NRAS (Q61R) and NRAS (Q61K) mutations, respectively. Error bars represent standard error of mean from triplicate samples. (c) Loss of BAP1 is
also associated with diminished colony-forming capability. Error bars represent±standard deviation (SD), from at least three independent experiments. *Po0.05
and **Po0.01 by Student’s t-test. (d) Effects of BAP1 depletion on tumor growth in a xenograft model. One million A375(NTC), A375(shBAP1), C918(NTC), and
C918(shBAP1) cells were implanted subcutaneously in NOD-SCID-IL2G-null mice with matrigel in a 1:1 ratio and observed over the indicated time period. With
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diminished resting levels of survivin but did not abrogate
survivin decay upon MG132/cycloheximide treatment, BAP1
likely participates in the homeostatic maintenance of survivin
levels through other mechanisms beyond simple deubiquitina-
tion. Furthermore, co-immunoprecipitation experiments were
carried out but did not demonstrate direct protein–protein
interaction between BAP1 and survivin (data not shown).
BAP1 suppresses non-transformed melanocytes
Our findings so far support a role for BAP1 in melanoma cell
viability. However, BAP1’s effects may be different in non-
transformed cells. We thus chose to restore BAP1 in cells that
appear to exist in relative BAP1 deficiency. Studies were first
initiated in PHM-2, which lacked BAP1 protein, but neither
control vector nor BAP1-expressing cells could be sufficiently
recovered for experimentation. We next turned to an immorta-
lized but non-transformed melanocyte line, Pmel, which had
lower RNA levels of BAP1 compared with any of the melanoma
cells. As shown in Figure 5a, stable introduction of BAP1 into
Pmel cells (i.e., Pmel(BAP1)) reduced proliferation, colony-
forming capacity, and survivin levels. Interestingly, Pmel
(shBAP1) cells also exhibited a drop in survivin levels, albeit
less significant than in Pmel(BAP1), and a similar growth-
suppressed phenotype (Figure 5a). On the other hand, ectopic
expression of BAP1 in three distinct melanoma cell lines led to
a modest increase in survivin and proliferation (Figure 5b).
DISCUSSION
Although inactivating germline mutations of BAP1 have been
described in families prone to CM and ocular melanoma
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(Abdel-Rahman et al., 2011; Wiesner et al., 2011; Njauw
et al., 2012), the role of BAP1 in the pathogenesis of CM
outside of the familial context is not fully known. Somatic
mutations of BAP1 occur in only 5% of sporadic primary
melanomas (Wiesner et al., 2011), suggesting that sustained
BAP1 activity may have a critical function in tumor
maintenance. In this study, we discovered that melanoma
cells appear to defend their BAP1 protein levels, despite a
wide range of BAP1 RNA content. Furthermore, BAP1 appears
to have a role in regulating the levels of survival genes, such as
BIRC5/survivin, and in maintaining the growth of at least a
subset of melanomas.
BAP1 mRNA levels do not appear to be significantly
diminished in primary melanomas compared with nevi and
normal skin, although lower expression levels do correlate
with adverse features, such as the mitotic rate and ulceration,
and a worse outcome. Among metastatic cases, BAP1 mRNA
levels appear to be higher compared with those found in nevi
and normal skin. Using immunohistochemistry, Murali et al.,
(2013) also recently reported that BAP1 loss occurred in
only 5% of primary melanomas and was associated with
worsened survival––a finding that resonates with our results.
Interestingly, reduced BAP1 was observed more often in the
desmoplastic variant of melanomas where there is greater
fibroblastic investment. Although preliminary, PHFs in our
survey (Figure 1) expressed no BAP1 and may therefore
account for the lower observed staining. Overall, BAP1 is
rarely mutated in primary CM and its expression is generally
sustained, which is in sharp contrast to primary uveal
melanomas where over half of the cases exhibit a total
absence of BAP1 (Shah et al., 2013). Thus, the biologic
function of BAP1 may be different between the two types of
melanoma cells.
A second, somewhat unexpected finding is that BAP1
appears to be a survival factor in melanoma cells. BAP1
depletion diminished proliferation and enhanced apoptosis,
both in vitro and in vivo, and phenotypically inhibited tumor
growth in mice xenografts. These functional studies may
explain the consistent high level expression in nearly all
melanoma lines. Others have also observed growth arrest in
non-melanoma cancer cells (Dalinghaus et al., 1991; Kittler
et al., 2007; Machida et al., 2009, Testa et al., 2011) with loss
of BAP1. However, BAP1 is not universally required for
cellular viability as some PHMs and PHFs do not appear to
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express appreciable levels of BAP1 protein. Paradoxically,
recent findings have confirmed that BAP1 also promotes
growth and differentiation even in uveal melanomas where
loss of BAP1 expression is a common event (Matatall et al.,
2013). Germline Bap1 deletion in mice is lethal during
embryogenesis, indicating that fetal growth and development
requires this gene (Dey et al., 2012). Thus, the specific
phenotype that results from BAP1 disruption may be dictated
by the balance of growth-restricting and growth-promoting
effects that are regulated by BAP1. This context-specific effect
is supported by our early results with the Pmel cells,
suggesting that BAP1 may harbor altogether different
properties in non-transformed cells.
Our studies reveal that BAP1 also impinges on the intracel-
lular metabolism of survivin, although the precise mechanistic
details are still under investigation. In a microarray profiling
experiment, survivin mRNA was also reported to be signifi-
cantly decreased in U2OS cells that have been depleted of
BAP1 (Yu et al., 2010). Gene expression studies, however,
may not fully uncover all BAP1 targets. In our hands, C918
uveal melanoma cells show sustained, if not slightly higher,
BIRC5 mRNA levels upon BAP1 suppression, despite a near
absence of BAP1 protein levels (Figure 4a). Thus, it appears
that BAP1 could regulate target proteins at both transcriptional
and the post-transcriptional levels (Yu et al., 2010; Bott et al.,
2011; Carbone et al., 2013).
There are several limitations to our study. As BAP1 is
differentially expressed in primary melanocytes, the role of
BAP1 in non-malignant cells may be functionally distinct from
that in their malignant counterparts. This could resolve the
apparent paradox between germline predisposition and cel-
lular dependence. Studies are underway to examine the
cooperative effects of BAP1 loss, or gain, with other oncogenic
alleles in human melanocytes. In addition, the type and
position of the reported mutations may bear on the suppres-
sive or oncogenic nature of the altered BAP1 proteins. We are
in the process of performing a more refined genotype–
phenotype correlation on the cellular level. Finally, the
biology of BAP1 will likely require a full annotation of BAP1
targets, both as direct enzymatic substrates and as indirect co-
regulators of transcription.
In summary, we provide early but provocative evidence that
BAP1 has an important growth-sustaining role in many CMs
and that some of the growth-retarding effects of BAP1 loss may
be mediated by viability factors such as survivin. These studies
also suggest that BAP1 could have a different role in non-
malignant cells and highlight the complex nature of genetic
and functional attributes of BAP1 biology.
MATERIALS AND METHODS
Cellular proliferation, colony formation, cell cycle, and
apoptosis assays
These assays were performed as previously described by our
laboratory (Udayakumar et al., 2011; Ji et al., 2012; Ji et al., 2013).
The PrestoBlue cell viability assay was performed as per the
manufacturer’s instruction (Life Technologies, Grand Island, NY).
After trypsinization and trypan Blue staining (Sigma-Aldrich, St Louis,
MO), viable cells were plated at a density of 103 cells per well in
black 96-well plates. Cell proliferation assays were performed at 24-
hour intervals for up to 6 days. Briefly, PrestoBlue dye was added, at
1/10 of the culture medium volume, and incubated for 10 minutes at
37 1C. The reaction was stopped with 15ml per well of 1 SDS (Life
Technologies), and the fluorescence was measured at 540 nm
excitation and 590 nm emission using a microplate reader
(SpectraMaxplus 1311, Molecular Devices, Sunnyvale, CA). Raw
fluorescence values were subtracted from the background of the
no-cell control wells for each experimental well. All experiments
were performed at least three times in triplicate under each condition.
For the colony formation assay, short-hairpin RNA-BAP1 and non-
target shRNA control (NTC)-transduced melanoma cells were plated
at 100–200 cells per ml per well into 12-well plates and kept in a
humidified CO2 incubator at 37 1C for 15–20 days (Udayakumar
et al., 2011; Ji et al., 2012; Ji et al., 2013). Cells were then washed
with cold 1 phosphate-buffered saline and fixed in 100% methanol
for 30 minutes at room temperature and stained with crystal violet
0.5% w/v for 30 minutes. The stained colonies were counted under
the stereo microscope and compared with a non-targeted control.
Colony-forming capacity or plating efficiency was expressed as a ratio
of the number of colonies consisting of X50 cells to the number of
cells seeded.
Cells were processed for cell cycle and apoptosis experiments
concurrently. Cell cycle analyses were performed to evaluate the
distribution of cells in various cell cycle phases (subG1, G1, S, and
G2/M) by measuring the DNA content of nuclei labeled with
propidium iodide (Life Technologies). Briefly, BAP1-depleted and
control A375, SKmel-119, and C918 viable cells were plated at
0.3 106 cells per well in six-well tissue culture plates and incubated
for 6–7 days at 37 1C in 5% CO2. At 6–7 days post lentiviral infection,
the cells were trypsinized then fixed with ice-cold ethanol final 70%
(v/v) at  20 1C overnight. Cells were centrifuged and washed twice
with cold 1 phosphate-buffered saline and re-suspended in 0.5 ml
of solution (20mg ml 1 of propidium iodide and 200mg ml 1 of
RNase in 0.1%Triton X-100) in phosphate-buffered saline (RNAse,
Becton Dickinson, San Jose, CA) and incubated at room temperature
in the dark for 30 minutes. Samples were then subjected to FACS (BD
FACS Calibur flow cytometer, BD Biosciences, Sparks Glencoe, MD).
Using the FlowJo, version 7.6.5 software (Ashland, OR) the Watson
model was used to calculate the percentages of cells in various cell
cycle phases. All experiments were performed at least three times in
triplicate.
For apoptosis, subG1 fractionation of cells with reduced DNA
content was determined at the time of cell cycle analysis. In
addition, apoptosis of short-hairpin RNA-BAP1 and NTC-transduced
melanoma cells (grown in complete (10%) or reduced (2.5%) serum
media) were determined using the Alexa Fluor 488 annexin-V
conjugate detection kit as per the manufacturer’s instructions (Life
Technologies). Briefly, melanoma cells (A375 and C918) were plated
(0.3 106 cells per well per ml) into six-well plates and incubated in
a 5% CO2 incubator at 37 1C for 6–7 days after transduction. Cells
were then trypsinized, centrifuged at 300g for 5 minutes, and stained
with Alexa Fluor 488 annexin-V and propidium iodide for 15 minutes
at room temperature in the dark. A total of 10,000 events were
analyzed for each sample on a flow cytometer FACS Verse, and
results were analyzed using FlowJo, version 7.6.5 software. The cell
cycle and apoptosis assays were performed in parallel and in
triplicate for each condition.
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Xenograft tumor growth assay
Nod-SCID-gamma mice (Jackson Laboratory, Bar Harbor, ME) were
injected subcutaneously with NTC-transduced or short-hairpin RNA-
BAP1-transduced A375 or C918 cells. The cells were mixed with
matrigel in 1:1 ratio (1 106 cells per mice in three to five mice per
group). Animal body weights and tumor development were mon-
itored and dimensions were measured by a Mitutoyo caliper (MSC,
Melville, NY) once to twice per week. Tumor volume was calculated
using mm3¼ lengthwidth2 0.5. Animals were maintained in
well-ventilated animal facility and tested in accordance with the
MGH Animal Care and Use Committee guidelines. Data were
expressed as mean±standard error of mean. Tumor histology was
confirmed by hematoxylin/eosin staining of formalin-fixed tissue.
Animal material
The mice experiments were performed in accordance with a protocol
approved by the Institutional Animal Care and Use Committee
(IACUC) of MGH.
Patient material
The experiments on patient specimens were approved by the local
ethics committee of the Lund University, Lund, Sweden (Katja et al.,
2012).
Statistical analysis
Data from different experiments were represented as means±stan-
dard deviation from at least three independent experiments. To
analyze cell viability, linear regression analysis was performed using
GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA). Significance
was established at Po0.05, as customary.
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